VVD 844

Key Product Details

Product Description

VVD 844 is a potent inhibitor of the PI3K/p110_α interaction (IC₅₀ = 4 nM) and the phosphorylated-Ser⁴⁷³-AKT (pAKT) pathway (IC₅₀ = 11 nM). It covalently binds cysteine 242 in the RAS domain of PI3K/p110_α and blocks RAS activation of PI3K_α activity in vitro.

In vivo, VVD 844 slows growth of RAS mutant tumors and human epidermal growth factor receptor 2 (HER2)-overexpressing tumors, without causing hyperglycemia. Exhibits synergistic effects with Sotorasib (Cat. No. 7713) and Adagrasib (Cat. No. 7488). VVD 844 is orally bioavailable.

Licensing Information

Sold with permission from Vividion Therapeutics

Product Specifications for VVD 844

The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.

Solubility

Preparing Stock Solutions for VVD 844

The following data is based on the product molecular weight 464.94.

Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which all affect the solvent volumes required to prepare stock solutions.

Select a batch to recalculate based on the batch molecular weight:

1 Recalculate

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	2.15 mL	10.75 mL	21.51 mL
5 mM	0.43 mL	2.15 mL	4.30 mL
10 mM	0.22 mL	1.08 mL	2.15 mL
50 mM	0.04 mL	0.22 mL	0.43 mL

Calculators

Background References

References are publications that support the biological activity of the product.

• Klebba Covalent inhibitors of the PI3Kα RAS binding domain impair tumor growth driven by RAS and HER2. Science 2025 PMID: 41066541

Product Documents for VVD 844